Welcome to our dedicated page for Cbdmd SEC filings (Ticker: YCBD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hemp regulation pages, pet-health revenue tables, evolving FDA guidance—cbdMD’s SEC filings can feel like a maze. Whether you’re chasing the latest cbdMD insider trading Form 4 transactions or trying to understand how functional mushroom supplements fit into the balance sheet, the detail is dense and time-sensitive.
Stock Titan turns that complexity into clarity. Our AI reads every line the moment a document hits EDGAR, then delivers human-friendly takeaways you can act on. Want the cbdMD quarterly earnings report 10-Q filing distilled into segment-level sales trends? Prefer a one-page brief on litigation risks from the cbdMD annual report 10-K simplified? It’s all here, updated in real time and linked to raw filings for deep dives.
Use cases professionals rely on every day:
- Track cbdMD Form 4 insider transactions real-time to gauge executive sentiment
- Compare e-commerce vs. wholesale growth through our cbdMD earnings report filing analysis
- Scan cbdMD 8-K material events explained for FDA letters or supply-chain updates
- Review the cbdMD proxy statement executive compensation section without wading through appendices
Each filing type is mapped to what matters: 10-K risk factors decode hemp-law uncertainty, 10-Q trend tables spotlight pet-product momentum, 8-K alerts flag sudden regulatory changes, and Form 4 data highlights cbdMD executive stock transactions Form 4. With understanding cbdMD SEC documents with AI, you save hours and make decisions backed by complete, current information.
cbdMD, Inc. filed an S-1 registering the potential resale of up to 1,700,000 shares of common stock by selling shareholders. The registered shares are issuable upon conversion of Series B Convertible Preferred Stock sold on September 29, 2025 pursuant to Purchase Agreements. cbdMD will not receive proceeds from any resale of these shares.
The Series B Preferred is convertible at $1.00 per share, subject to anti‑dilution adjustments and a floor conversion price of $0.50 per share, and accrues dividends at 10% per annum, payable in cash or stock subject to equity conditions. A 4.99% beneficial ownership limitation applies to conversions. An exchange cap limits issuances without prior shareholder approval to 19.99% of pre‑transaction outstanding shares, identified as 1,782,518 shares.
Shares outstanding were 8,919,410 as of November 6, 2025. The company states 10,619,410 shares outstanding assuming full conversion at a $1.00 conversion price. cbdMD previously received $1,700,000 gross proceeds from the private placement of the Series B Preferred for working capital and general corporate purposes.
cbdMD, Inc. issued 1,700,000 shares of newly designated Series B Convertible Preferred Stock to four institutional investors for aggregate gross proceeds of
FAQ
What is the current stock price of Cbdmd (YCBD)?
What is the market cap of Cbdmd (YCBD)?
